Paper39769262
Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.
Carvalho LVDN and 6 others. Int J Mol Sci, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients. Papers, record 39769262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39769262
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Galectins | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Aged | |
| Prognosis | |
| Kidney | |
| Aged, 80 and over | |
| Adult | |
| Biomarkers, Tumor |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| n/a | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | PubMed | ||
| n/a | Conselho Nacional de Desenvolvimento Científico e Tecnológico | PubMed |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37569679 | Galectin-4 Is Involved in the Structural Changes of Glycosphingolipid Glycans in Poorly Differentiated Gastric Cancer Cells with High Metastatic Potential. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37569679 | PubMed |
| 2 | 20200560 | Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. | Leukemia | 2010 | https://conductscience.org/library/papers/20200560 | PubMed |
| 3 | 34290359 | Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. | Leukemia | 2022 | https://conductscience.org/library/papers/34290359 | PubMed |
| 4 | 22026577 | The fibrosis marker galectin-3 and outcome in the general population. | J Intern Med | 2012 | https://conductscience.org/library/papers/22026577 | PubMed |
| 5 | 24477688 | Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice. | Am J Physiol Renal Physiol | 2014 | https://conductscience.org/library/papers/24477688 | PubMed |
| 6 | 32138174 | Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. | Biomolecules | 2020 | https://conductscience.org/library/papers/32138174 | PubMed |
| 7 | 38868715 | Complex heatmap visualization. | Imeta | 2022 | https://conductscience.org/library/papers/38868715 | PubMed |
| 8 | 21912250 | Galectins and microenvironmental niches during hematopoiesis. | Curr Opin Hematol | 2011 | https://conductscience.org/library/papers/21912250 | PubMed |
| 9 | 34195077 | Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma. | Front Oncol | 2021 | https://conductscience.org/library/papers/34195077 | PubMed |
| 10 | 39539619 | The regulating role of galectin-9 in immune cell populations. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39539619 | PubMed |
| 11 | 30813402 | Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/30813402 | PubMed |
| 12 | 29975570 | Galectin-1 is a new fibrosis protein in type 1 and type 2 diabetes. | FASEB J | 2019 | https://conductscience.org/library/papers/29975570 | PubMed |
| 13 | 28435287 | Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation. | Onco Targets Ther | 2017 | https://conductscience.org/library/papers/28435287 | PubMed |
| 14 | 33771821 | Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells. | Cancer Immunol Res | 2021 | https://conductscience.org/library/papers/33771821 | PubMed |
| 15 | 35687787 | Plasma Galectin-9 Is a Useful Biomarker for Predicting Renal Function in Patients Undergoing Native Kidney Biopsy. | Arch Pathol Lab Med | 2023 | https://conductscience.org/library/papers/35687787 | PubMed |
| 16 | 17325894 | Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. | Leuk Lymphoma | 2007 | https://conductscience.org/library/papers/17325894 | PubMed |
| 17 | 28801238 | A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy. | EBioMedicine | 2017 | https://conductscience.org/library/papers/28801238 | PubMed |
| 18 | 29258207 | Role of Galectins in Multiple Myeloma. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/29258207 | PubMed |
| 19 | 28858976 | Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. | J Hypertens | 2018 | https://conductscience.org/library/papers/28858976 | PubMed |
| 20 | 37898403 | The universe of galectin-binding partners and their functions in health and disease. | J Biol Chem | 2023 | https://conductscience.org/library/papers/37898403 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42197247 | Galectin-3-A Multifunctional Molecule and a Key Player in Health and Disease. | Molecules | 2026 | https://conductscience.org/library/papers/42197247 | PubMed |
| 42054245 | Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer. | J Med Chem | 2026 | https://conductscience.org/library/papers/42054245 | PubMed |
| 41590658 | Plasma Galectin-7 (Gal-7) and Galectin-8 (Gal-8) as Emerging Biomarkers in Psoriasis: Associations with Disease Activity and Metabolic Status. | Metabolites | 2026 | https://conductscience.org/library/papers/41590658 | PubMed |
| 40572708 | Galectin-1 in Cardiovascular Pathogenesis: Unraveling Dual Roles and Mechanistic Insights in Emerging Research. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40572708 | PubMed |
| 40362377 | Acridine-Based Chalcone 1C and ABC Transporters. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362377 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HLA-G | 3135 | PubTator's text mining | https://conductscience.org/library/genes/3135 | NCBI Gene |
| LGALS9 | 3965 | PubTator's text mining | https://conductscience.org/library/genes/3965 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39769262
GET https://conductscience.org/api/papers/v1/39769262/references?page=2